Angiopoietin-2: A potential novel diagnostic marker in multiple myeloma

Clinical Biochemistry

Volumn 44, Issue 8-9, 2011, Pages 590-595

  Joshi, Suhasini ^a   Khan, Rehan ^a   Sharma, Manoj ^b   Kumar, Lalit ^c   Sharma, Alpana ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

^c INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Angiogenesis; Angiopoietins; Bone marrow microenvironment; Diagnostic marker; Multiple myeloma

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BETA 2 MICROGLOBULIN; CHEMOKINE; TUMOR MARKER; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; BONE MARROW; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MICROENVIRONMENT; MULTIPLE MYELOMA; NORMAL HUMAN; PRIORITY JOURNAL; SPECIES; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANGIOPOIETIN-1; ANGIOPOIETIN-2; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79955858205     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.01.010     Document Type: Article

References (48)

1. Folkman J. Tumor angiogenesis: therapeutic complications. N Engl J Med 1971, 285:1182-1186.
2. Bryan P.S., Kathy D.M. Angiogenesis of breast cancer. J Clin Oncol 2005, 23:1782-1790.
3. Stoeltzing O., Liu W., Reinmuth N., et al. Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol 2003, 10:722-733.
4. Herbst R.S., Onn A., Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005, 23:3243-3256.
5. Ferrara N., Gerber H.P., Le Couter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
6. Aguayo A., Kantarjian H., Manshouri T., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96:2240-2245.
7. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95:309-313.
8. Vacca A., Ribatti D., Roncali L., et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994, 87:503-508.
9. Vacca A., Di Loreto M., Ribatti D., et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1 and CD44. Am J Hematol 1995, 50:9-14.
10. Ribatti D., Vacca A., Nico B., et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999, 79:451-455.
11. Rajkumar S.V., Leong T., Roche P.C., et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000, 6:3111-3116.
12. Vacca A., Ribatti D., Presta M., et al. Bone marrow vascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064-3073.
13. Kuku I., Aydogdu I., Bayraktar N., et al. Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma. Cell Biochem Funct 2005, 23:47-50.
14. Richard A.G., Thomas J.K., Barbara A.O., Janis K. Immunology. Antibodies: structure and function 2004, 79. W H Freeeman & Co, New York. 5th ed.
15. Liesveld J.L., Harbol A.W., Belanger T., et al. MIP-1alpha and TGF-beta production in CD34+ progenitor-stromal cell coculture systems: effects of progenitor isolation method and cell-cell contact. Blood Cells Mol Dis 2000, 26:261-275.
16. Gupta D., Treon S.P., Shima Y., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950-1961.
17. Sharma A., Rajappa M., Saxena A., Sharma M. Cytokine profile in Indian females with cervical intraepithelial neoplasia and cancer cervix. Int J Gynecol Cancer 2007, 17:879-885.
18. Satyam A., Singh P., Badjatia N., et al. A disproportion of Th1/Th2 cytokines with predominance of Th2, in urothelial carcinoma of bladder. Urol Oncol 2011, 29:58-65.
19. Sharma A., Khan R., Joshi S., et al. Dysregulation in Th1/Th2 cytokine ratios in multiple myeloma patients. Leuk Lymphoma 2010, 51:920-927.
20. Sharma A., Tripathi M., Satyam A., Kumar L. Study of antioxidant levels in patients with multiple myeloma. Leuk Lymphoma 2009, 50:691-693.
21. Jakob C., Sterz J., Zavrski I., et al. Angiogenesis in multiple myeloma. Euro J Can 2005, 42:1581-1590.
22. Suri C., Jones P.F., Patan S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic stage. Cell 1996, 87:1171-1180.
23. Suri C., McClain J., Thurston G., et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998, 282:468-471.
24. Thurston G., Rudge J.S., Ioffe E., et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000, 6:460-463.
25. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts In vivo angiogenesis. Science 1997, 277:55-60.
26. Lobov I.B., Brooks P.C., Lang R.A. Angiopoietin-2 displays the VEGF-dependent modulation of capillary structure and endothelial survival in vitro. PNAS 2002, 99:11205-11210.
27. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
28. Ferrara N., Gerber H.P., Le C.J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
29. Di Raimondo F., Azzaro M.P., Palumbo G., et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000, 85:800-805.
30. Verstovsek S., Kantarjian H., Estey E., et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 2001, 15:1165-1170.
31. Kline M., Donovan K., Wellik L., et al. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res 2007, 31:591-598.
32. Zdzisińska B., Walter-Croneck A., Dmoszyńska A., Kandefer-Szerszeń M. Matrix metalloproteinase and cytokine production by bone marrow adherent cells from multiple myeloma patients. Arch Immunol Ther Exp Warsz 2006, 54:289-296.
33. Negaard H.F., Iversen N., Bowitz-Lothe I.M., et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009, 23:162-169.
34. Vacca A., Ria R., Ribatti D., et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumour angiogenesis and growth in multiple myeloma. Haematologica 2003, 88:176-185.
35. Vacca A., Scavelli C., Montefusco V., et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005, 23:5334-5346.
36. Giuliani N., Colla S., Lazzaretti M., et al. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003, 102:638-645.
37. Uneda S., Matsuno F., Sonoki T., et al. Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Haematologica 2003, 88:113-115.
38. Quartarone E., Alonci A., Allegra A., et al. Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies. Eur J Haematol 2006, 77:480-485.
39. Kastritis E., Roussou M., Michael M., et al. High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. Br J Haematol 2010, 150:587-591.
40. Schliemann C., Bieker R., Padro T., et al. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 2006, 91:1203-1211.
41. Martinelli S., Maffei R., Castelli I., et al. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. Leuk Res 2008, 32:593-597.
42. Oh H., Tagaki H., Suzama K., et al. Hypoxia and vascular endothelial growth factor up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999, 274:15732-15739.
43. Jones P.F. Not just angiogenesis-wider roles for the angiopoietins. J Pathol 2003, 201:515-527.
44. Anagnostopoulos A., Eleftherakis-Papaiakovou V., Zervas K., et al. Serum concentrations of angiogenic cytokines in Waldenstrom's macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol 2007, 23:560-568.
45. Anargyrou K., Terpos E., Vassilakopoulos T.P., et al. Greek Myeloma Study Group. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica 2008, 93:451-454.
46. Ramakrishnan V., Timm M., Haug J.L., et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2009, 1-13.
47. Bach F., Uddin F.J., Burke D. Angiopoietins in malignancy. Eur J Surg Oncol 2007, 33:7-15.
48. Oliner J., Min H., Leal J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.